New York, NY -- (SBWIRE) -- 01/24/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Coronado Biosciences Inc (NASDAQ:CNDO), Oclaro, Inc (NASDAQ:OCLR), WidePoint Corporation (NYSEMKT:WYY), CytRx Corporation (NASDAQ:CYTR)
Coronado Biosciences Inc (NASDAQ:CNDO) showed a volume of 1.40 million shares by the end of last trade whereas the average volume of the stock remained 2.76 million shares. The stock opened the session at $2.96 but then moved to $3.01. At that price, the stock showed a positive performance of 3.08%. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
Will CNDO Continue To Move Higher? Find Out Here
Oclaro, Inc (NASDAQ:OCLR) opened the session at $2.76 and closed the session at $2.73. The stock showed a negative performance of -1.80% in previous trading session. Traded with volume of 1.40 million shares in the prior session and the average volume of the stock remained 1.13 million shares. Oclaro, Inc. is a provider of optical communications and laser components, modules and subsystems for a range of markets, including telecommunications (telecom), industrial, scientific, consumer electronics and medical. The Company’s product offerings include tunable laser, lithium niobate external modulators, pump laser chips, thin film filters, and amplifiers.
Has OCLR Found The Bottom And Ready To Gain Momentum? Find Out Here
WidePoint Corporation (NYSEMKT:WYY) opened the session at $1.69and closed the session at $1.59. The stock showed a negative performance of -5.92% in previous trading session. Traded with volume of 1.39 million shares in the prior session and the average volume of the stock remained 1.65 million shares. The beta of the stock remained 0.85. WidePoint Corporation (WidePoint) is a provider of customized technology-based products and solutions to both the government sector and commercial markets. The Company operates in three segments: Communications Management,
Why Should Investors Buy WYY After the Recent Fall? Just Go Here and Find Out
CytRx Corporation (NASDAQ:CYTR) the stock decreased -2.08% and finished the session at $7.07. Traded with volume of 1.39 million shares in the prior session and the average volume of the stock remained 6.34 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
Will CYTR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)